menu
    • menu
    [{"orgOrder":0,"company":"Minerva Biotechnologies","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2023","type":"Inapplicable","leadProduct":"huMNC2-CAR22","moa":"MUC1","graph1":"Oncology","graph2":"Phase I","graph3":"Minerva Biotechnologies","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Minerva Biotechnologies \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Minerva Biotechnologies \/ Undisclosed"},{"orgOrder":0,"company":"Minerva Biotechnologies","sponsor":"Memorial Sloan Kettering Cancer Center","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2020","type":"Licensing Agreement","leadProduct":"huMNC2-CAR44","moa":"MUC1","graph1":"Oncology","graph2":"Phase I","graph3":"Minerva Biotechnologies","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Minerva Biotechnologies \/ Minerva Biotechnologies","highestDevelopmentStatusID":"6","companyTruncated":"Minerva Biotechnologies \/ Minerva Biotechnologies"},{"orgOrder":0,"company":"Minerva Biotechnologies","sponsor":"City of Hope","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2019","type":"Inapplicable","leadProduct":"huMNC2-CAR44 CAR-T cell","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Minerva Biotechnologies","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Minerva Biotechnologies \/ City of Hope","highestDevelopmentStatusID":"6","companyTruncated":"Minerva Biotechnologies \/ City of Hope"}]

    Find Clinical Drug Pipeline Developments & Deals by Minerva Biotechnologies

    Menu

    Minerva Biotechnologies

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Minerva Biotechnologies

                            U.S.A arrow
                            Global ChemShow
                            Not Confirmed

                            Minerva Biotechnologies

                            U.S.A arrow
                            Global ChemShow
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : huMNC2-CAR22

                            Therapeutic Area : Oncology

                            Study Phase : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Minerva Biotechnologies Gets FDA Approval of IND for a MUC1*-CAR-1XX with Increased Persistence and Ability to...

                            Details : huMNC2-CAR22 bears the “1XX” mutations in the T cell’s CD3-z signaling domain, targeting MUC1*, the growth factor receptor that drives the growth and metastasis of most solid tumor cancers.

                            Product Name : Undisclosed

                            Product Type : Cell & Gene Therapy

                            Upfront Cash : Inapplicable

                            January 09, 2023

                            Lead Product(s) : huMNC2-CAR22

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Minerva Biotechnologies

                            U.S.A arrow
                            Global ChemShow
                            Not Confirmed

                            Minerva Biotechnologies

                            U.S.A arrow
                            Global ChemShow
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : huMNC2-CAR44

                            Therapeutic Area : Oncology

                            Study Phase : Phase I

                            Recipient : Memorial Sloan Kettering Cancer Center

                            Deal Size : Undisclosed

                            Deal Type : Licensing Agreement

                            DEALS_DEV arrow-down

                            Minerva Biotechnologies Announces License Agreement with Memorial Sloan Kettering Cancer Center for 1XX Techno...

                            Details : Minerva Biotechnologies has licensed from Memorial Sloan Kettering Cancer Center (MSK) “1XX” technology for use with Minerva’s proprietary anti-MUC1* antibodies to increase CAR T cell persistence in patients.

                            Product Name : Undisclosed

                            Product Type : Cell & Gene Therapy

                            Upfront Cash : Undisclosed

                            June 22, 2020

                            Lead Product(s) : huMNC2-CAR44

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I

                            Recipient : Memorial Sloan Kettering Cancer Center

                            Deal Size : Undisclosed

                            Deal Type : Licensing Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Minerva Biotechnologies

                            U.S.A arrow
                            Global ChemShow
                            Not Confirmed

                            Minerva Biotechnologies

                            U.S.A arrow
                            Global ChemShow
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : huMNC2-CAR44 CAR-T cell

                            Therapeutic Area : Oncology

                            Study Phase : Phase I

                            Sponsor : City of Hope

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Autologous huMNC2-CAR44 or huMNC2-CAR22 T Cells for Breast Cancer Targeting Cleaved Form of MUC1 (MUC1*)

                            Details : HuMNC2-CAR44 CAR-T cell is a Cell and Gene Therapy drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Breast Neoplasms.

                            Product Name : Undisclosed

                            Product Type : Cell & Gene Therapy

                            Upfront Cash : Inapplicable

                            July 16, 2019

                            Lead Product(s) : huMNC2-CAR44 CAR-T cell

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I

                            Sponsor : City of Hope

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth